The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
World Lung 2024 – picking apart the Harmoni-2 win
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
Why Astra won’t find bladder cancer domination easy
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
Replimune goes pivotal in uveal melanoma
The group eyes a broader use than Immunocore’s Kimmtrak.
